Number of the records: 1
linagliptín
SYS d000069476 LBL 00000nz--a2200181n--4500 005 20250606221749.3 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D03.633.100.759.562 065 $a D03.633.100.786.563 066 $a 01 $c 03 150 $a linagliptín $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a BI 1356 $2 slo 550 $7 sllk_us_auth*d000068900 $Y Sitagliptin Phosphate $w b $a sitagliptín fosfát 550 $7 sllk_us_auth*d007004 $Y Hypoglycemic Agents $w P $a hypoglykemiká 550 $7 sllk_us_auth*d054795 $Y Incretins $w P $a inkretíny 550 $7 sllk_us_auth*d054873 $Y Dipeptidyl-Peptidase IV Inhibitors $w P $a inhibítory dipeptidylpeptidázy 4 550 $7 sllk_us_auth*d000068900 $Y Sitagliptin Phosphate $w p $a sitagliptín fosfát 665 $a 2016 (2011) $2 eng 680 9-
$i A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. $2 eng 750 -2
$a Linagliptin $2 eng 980 $x M
Number of the records: 1